Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Core Insights - Adverum Biotechnologies announced promising results from the 26-week interim analysis of the LUNA Phase 2 trial for Ixo-vec, a gene therapy for wet age-related macular degeneration (AMD), indicating a favorable safety and efficacy profile [1][2][6] Efficacy - 76% of patients receiving the 6E10 dose of Ixo-vec were injection-free at 26 weeks, maintaining visual acuity and fluid control [1][7] - Both 6E10 and 2E11 doses showed maintenance of visual and anatomic outcomes, with 83% of patients in the 2E11 cohort also being injection-free [6][7] - The mean annualized anti-VEGF injections were reduced by 90% for the 6E10 group and 95% for the 2E11 group at week 26 [7] Safety - 100% of patients receiving the difluprednate-alone prophylactic regimen had no or minimal inflammation, with no additional corticosteroids needed beyond scheduled prophylaxis [1][9] - Ixo-vec was well tolerated, with no serious adverse events related to the treatment and only mild to moderate adverse events reported [7][9] Patient Preference - A Patient Preference Survey indicated that 88% of patients preferred Ixo-vec over previous anti-VEGF treatments, and 93% would choose to receive Ixo-vec in the other eye if applicable [1][9] Upcoming Milestones - Key upcoming events include the presentation of the 9-month analysis and updates on Phase 3 trial design anticipated in Q4 2024, with the initiation of the Phase 3 trial planned for H1 2025 [10]